NEW YORK, May 6, 2009 (GLOBE NEWSWIRE) -- Peabody PLLC is investigating possible violations of federal securities law by Sequenom, Inc. ("Sequenom" or the "Company") (Nasdaq:SQNM). The investigation focuses on, among other things, whether Sequenom violated the Securities Exchange Act of 1934 by issuing materially false and misleading statements regarding the Company's SEQureDX, Down Syndrome test under development. Specifically, the investigation focuses on allegations that certain officers and directors of the Company failed to properly disclose that Sequenom employees mishandled test data and results regarding the Down Syndrome test.
On April 29, 2009, Sequenom disclosed that the Company's employees had mishandled data that invalidates previous statements about the effectiveness of the prenatal Down Syndrome test. On this news, shares of Sequenom declined $11.29 per share, more than 75%, to close at $3.62 per share on April 30, 2009.
Shareholders who purchased Sequenom common stock in the open market between June 4, 2008 and April 29, 2009, or on the company's public offering on June 26, 2008, with questions concerning their legal rights are encouraged to contact us at the information below.